L&T-TECHNOLOGY-SERVICES
3.2.2021 08:32:07 CET | Business Wire | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), India’s leading pure-play engineering services company, has been recognized as a ‘Leader’ for Development and Verification & Validation services in Industry 4.0 by the consulting and research firm, Everest Group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210202006249/en/
In its report, ‘PEAK Matrix® for Industry 4.0 Service Provider 2020,’ Everest Group has identified LTTS among the six leading companies in the market based on various parameters such as market adoption, portfolio mix, value delivered, innovation & investments, delivery footprint, and vision and strategy.
According to Everest Group, LTTS has a strong ability to drive a high level of innovation around Industry 4.0 that customers recognize, buoyed by robust investments in establishing dedicated infrastructure, developing a strong partner ecosystem and enhancing IP assets for Industry 4.0 services.
The objective of the PEAK Matrix is to provide a data-driven assessment of service and technology providers based on their overall capability and market impact across different global services markets, classifying them into “Leaders”, “Major Contenders”, and “Aspirants”.
“LTTS’ focus on development and Verification and Validation (V&V) in the Industry 4.0 segment is evident from the fact that this service function accounts for over 50% of the firm’s revenue from Industry 4.0 services,” said Akshat Vaid, Vice President, Everest Group . “The firm’s dedicated investments in V&V labs infrastructure and CoEs catering to next-generation themes such as IIoT, AI/ML, cloud engineering, robotics, and cybersecurity have significantly elevated its positioning among enterprises as a reliable Industry 4.0 service provider.”
“Additionally, LTTS’ focus on IP development is reflected in a suite of solutions, including modular frameworks and platforms such as Aikno, nB-oN, and DFX, which helps enterprises enhance productivity and speed-to-impact in Industry 4.0 initiatives. LTTS’ vision for this space, along with focused investments have helped them achieve a strong growth momentum in this market,” Mr Vaid added.
Amit Chadha, Deputy CEO and Member of the Board at L&T Technology Services said, “The advancements in the Industry 4.0 landscape have witnessed rapid traction with businesses across sectors realizing its true potential. With a rich engineering DNA combined with our leadership position in engineering services, LTTS has been at the forefront of introducing pioneering innovations in this space. We are delighted to receive this latest recognition from an independent research body as globally acclaimed as Everest Group and further resolve to usher in newer benchmarks in the domain of Industry 4.0.”
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 53 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 16,000 employees spread across 17 global design centers, 28 global sales offices and 62 innovation labs as of December 31, 2020.
For more information please visit https://www.ltts.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202006249/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom